Validation pour Ingenuity407

vers la météo de la validation par utilisateur

Ingenuity407

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 81 - PMID ?

Oral administration of NODE ( with a treatment period of 2 weeks ) is involved in expression of SP NODE mRNA in muscle from SP that involves mutant SP NODE gene ( unspecified homozygous gene mutation ) in SP .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 1

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 2

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 3

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 4

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 5

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 6

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 7

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 8

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 9

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 10

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 11

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 12

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 13

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 14

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 15

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 16

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 17

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 18

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 19

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 20

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 21

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 22

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 23

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 24

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 25

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 26

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 27

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 28

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 29

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 30

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 31

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 32

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 33

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 34

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 35

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 36

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 37

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 38

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 39

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 40

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 41

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 42

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 43

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 44

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 45

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 46

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 47

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 48

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 49

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 50

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 51

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 52

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 53

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 54

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 55

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 56

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 57

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 58

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 59

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 60

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 61

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 62

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 63

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 64

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 65

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 66

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 67

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 68

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 69

                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 70

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 71

                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 72

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 73

                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 74

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 75

                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 76

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 77

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 78

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 79

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 80

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 81

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 82

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 83

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 84

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 85

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 86

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 87

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 88

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 89

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 90

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 91

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 92

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 93

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 94

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 95

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 96

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 97

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 98

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 99

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 100

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 101

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 102

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 103

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 104

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 105

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 106

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 107

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 108

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 109

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 110

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 111

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 112

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 113

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 114

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 115

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 116

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 117

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 118

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 119

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 120

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 121

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 122

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 123

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 124

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 125

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 126

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 127

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 128

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 129

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 130

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 131

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 132

                                                                                            +--------------------------SUBJ:V-N--------------------------+                                                                                    
                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 133

                                                                                            +--------------------------SUBJ:V-N--------------------------+                                                                                    
                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 134

                                                                                            +--------------------------SUBJ:V-N--------------------------+                                                                                    
                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 135

                                                                                            +--------------------------SUBJ:V-N--------------------------+                                                                                    
                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 136

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 137

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 138

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 139

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 140

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 141

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 142

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 143

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 144

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 145

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 146

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 147

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               +----------------COMP:V_PASS-N(in)---------------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 148

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 149

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 150

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 151

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 152

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 153

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 154

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 155

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 156

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 157

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 158

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 159

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 160

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 161

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 162

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 163

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 164

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 165

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 166

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 167

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 168

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 169

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 170

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 171

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 172

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 173

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 174

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 175

                                                                               +---------------------COMP:V_PASS-N(from)--------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 176

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 177

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 178

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 179

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 180

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 181

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 182

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 183

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 184

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 185

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 186

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 187

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +----------------COMP:V_PASS-N(in)---------------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,muscle)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 188

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 189

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 190

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 191

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               +---------------------COMP:V_PASS-N(from)--------------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 192

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 193

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 194

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 195

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 196

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 197

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 198

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 199

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 200

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 201

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 202

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 203

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 204

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 205

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 206

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 207

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 208

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 209

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 210

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 211

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 212

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 213

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 214

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 215

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 216

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 217

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 218

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 219

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 220

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 221

                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 222

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 223

                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 224

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 225

                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 226

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                                                                                         |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 227

                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 228

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 229

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 230

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 231

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 232

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 233

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 234

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 235

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 236

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 237

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 238

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 239

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 240

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 241

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 242

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 243

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 244

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 245

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 246

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 247

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 248

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 249

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 250

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 251

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 252

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 253

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 254

                                                                                                                                                         +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 255

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 256

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 257

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 258

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 259

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 260

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 261

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 262

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 263

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 264

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 265

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 266

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+-------------SUBJ:V-N------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 267

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +------------COMP:N-N(in)-----------+                                               +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        +--------SUBJ:V-N--------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,muscle)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 268

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 269

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 270

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 271

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 272

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 273

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 274

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 275

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 276

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 277

                                                                                            +--------------------------SUBJ:V-N--------------------------+----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 278

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |                                                                                                +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+-------------SUBJ:V-N------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,mRNA)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 279

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +-----------------COMP:N-N(from)----------------+                                                                                            |    
                                                                               |            +------------COMP:N-N(in)-----------+           |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 280

                                                                                            +--------------------------SUBJ:V-N--------------------------+                                                                                    
                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 281

                                                                                            +--------------------------SUBJ:V-N--------------------------+                                                                                    
                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 282

                                                                                            +--------------------------SUBJ:V-N--------------------------+                                                                                    
                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 283

                                                                                            +--------------------------SUBJ:V-N--------------------------+                                                                                    
                                                                                            +-----------------COMP:N-N(from)----------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 284

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 285

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 286

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 287

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                                 |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 288

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 289

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 290

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 291

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                                 +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+---COMP:N-N(from)---+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
COMP:N-N(from) (mRNA,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 292

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 293

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 294

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 295

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+                        |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |                        +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |                        |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        +COMP:N-N(fr+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(from) (muscle,__SP__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 296

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 297

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 298

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 299

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+                    |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+                    |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+COMP:N-N+           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(in) (mRNA,muscle)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 300

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 301

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 302

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 303

                                                                               +--------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------+    
                                                                               |            +--------------------------SUBJ:V-N--------------------------+                                                                               |    
                                                                               |            +-----------------COMP:N-N(from)----------------+            |                                                                               |    
                                                                               |            +------------COMP:N-N(in)-----------+           |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            +-------COMP:N-N(of)-------+        |           |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           +-MOD_ATT:N-ADJ+        |           |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |       +MOD_AT+        |           |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |       |      |        |           |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ __NODE__ mRNA in muscle from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(in) (expression,muscle)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (involve,expression)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)